Related Experiment Video
Updated: Aug 24, 2026

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
Published on: March 24, 2019
NF-κB across the Alzheimer disease spectrum: Context-dependent protective and pathogenic roles
Ali Azargoonjahromi1, Fatemeh Abutalebian2, Hamide Nasiri3
1Shiraz University of Medical Sciences, Shiraz, Iran.
None:
Nuclear factor kappa B (NF-κB) has been implicated in both protective and detrimental processes in Alzheimer disease (AD), creating an apparent contradiction in the literature. Increasing evidence, however, indicates that these divergent effects reflect differences in cell type, molecular configuration, activation kinetics, disease state, and the surrounding pathological environment rather than a true biological paradox. Under transient and tightly regulated conditions, NF-κB can support neuronal survival, stress adaptation, antioxidant defense, and selected compensatory responses to amyloid-β pathology. In contrast, persistent or disease-conditioned signaling is more consistently associated with amyloidogenic processing, tau propagation, chronic neuroinflammation, impaired proteostasis, neuronal dysfunction, and neurovascular injury. The available evidence therefore supports an asymmetric framework in which protective effects are confined to relatively specific molecular and temporal settings, whereas sustained pathological signaling is supported across a broader range of disease-relevant models and cellular processes. This distinction argues against indiscriminate activation or global inhibition of NF-κB, either of which could disrupt physiological functions while failing to selectively suppress disease-driving pathways. Therapeutic strategies should instead target defined pathological NF-κB programs within the relevant cell type and disease context while preserving adaptive and homeostatic signaling. This review synthesizes the context-dependent roles of NF-κB in AD and provides a framework for reconciling its apparently opposing effects.
Related Concept Videos
Alzheimer Disease ll: Pathophysiology
Alzheimer Disease l: Introduction
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Parkinson Disease ll: Pathophysiology
